Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
March 7, 2023 03:16 PM ESTUpdated 04:17 PM
Pharma

Ab­b­Vie braces for 'greater ero­sion' of Hu­mi­ra fran­chise in sec­ond half of this year

Nicole DeFeudis

Editor

Ab­b­Vie ex­ecs tout­ed a wave of Rin­voq pro­grams at Cowen’s an­nu­al con­fer­ence on health­care Tues­day as they brace for a tougher Hu­mi­ra bat­tle in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

A service from the Financial Times